TECHNOLOGY LICENSING OPPORTUNITY: SmartBind pH Switch
Energy, Department of · ENERGY, DEPARTMENT OF
This notice is not accepting responses (deadline was Dec 4, 2025, 7:00 PM EST).
Page kept for research and related open opportunities below. For current work in this category, use the related notices or browse hubs.
- Response deadline
- Dec 4, 2025, 7:00 PM EST
- Posted
- Nov 12, 2025
- Solicitation
- S-133461
- Set-aside
- No Set aside used
- Place of performance
- Los Alamos, NM, USA
- Contracting office
- TRIAD - DOE CONTRACTOR · Columbus · OH
- Source
- SAM.gov · updated May 9, 2026
Description
This innovation from scientists at Los Alamos National Laboratory is a significant improvement on a gold standard protein purification method that gently captures and releases antibodies using mild pH changes, making antibody purification safer, more efficient, and less damaging. The Challenge: Purifying antibodies � vital tools in medicine and research � typically relies on a protein called Protein G that latches onto them. However, getting the antibodies back off this molecular �magnet� requires very acidic conditions, which can damage both the antibodies and Protein G itself. This harsh process risks ruining expensive materials and reducing the effectiveness of critical therapies and tests. Problems Solved: Researchers engineered a pH-switchable version of Protein G that uses gentle changes in acidity (pH) to control when it releases antibodies, it now binds antibodies at a mildly acidic pH and releases at a mildly basic pH � eliminating the need for harsh chemicals. This innovation protects sensitive proteins, improves efficiency, lowers costs, and opens the door for safer, greener, and more effective antibody purification in both labs and industry. Key Advantages: Gentle elution conditions: Antibodies are released at a mild pH (~8.2) instead of harsh acidic conditions (~2.7), reducing damage to both the antibodies and the protein itself. Improved antibody stability and yield: Preserving antibody structure increases reliability and effectiveness, which is especially critical for therapeutic and diagnostic use. Switchable binding mechanism: pH-sensitive histidine residues allow for a controlled "on/off" switch based on pH, improving process control and reproducibility. Cost-effective and scalable: Reduces loss of expensive antibodies and minimizes the need for post-purification repair or replacement, saving money in industrial applications. Market Applications: Biopharmaceuticals Life Sciences Research Bioprocessing and Manufacturing Tools Veterinary and Agricultural Biotech Development Status: TRL 4 US Provisional / Patent No. 10,954,275 LA-UR-25-29451 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL�s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search
What similar awards have paid
Real federal awards already on the books in a similar lane — so you can size the opportunity, not guess. This is public history, not a bid price, cost estimate, or prediction that you will win.
Typical award size
$97,741
Middle of the pack for similar past awards
Most similar awards fall between $38,257 and $252,048
Who has won work like this
Public awardees in this lane — useful for competitor scan or teaming ideas, not a ranked list of “best” firms.
- 1CEPHEID63 awards$42.65M
- 2BIOMERIEUX INC55 awards$12.60M
- 3ROCHE DIAGNOSTICS CORPORATION57 awards$11.06M
- 4BIOFIRE DIAGNOSTICS LLC12 awards$7.92M
- 5ABBOTT MOLECULAR INC.11 awards$7.12M
- 6FISHER SCIENTIFIC COMPANY L.L.C.20 awards$3.67M
- 7WERFEN USA LLC37 awards$3.34M
- 8LEICA MICROSYSTEMS INC.7 awards$2.79M
Recent examples
A few of the newest similar awards in our index.
- ALBA BIOSCIENCE, INC.Sep 30, 2025Department of Veterans Affairs$37,685Source
- BINDING SITE, INC., THESep 30, 2025Department of Veterans Affairs$288,396Source
- BECTON, DICKINSON AND COMPANYSep 30, 2025Department of Veterans Affairs$41,345Source
- IMMUNO MYCOLOGIES INCSep 30, 2025Department of Veterans Affairs$83,553Source
- ORTHO-CLINICAL DIAGNOSTICS INCSep 29, 2025Department of Veterans Affairs$95,216Source
- WERFEN USA LLCSep 29, 2025Department of Veterans Affairs$29,232Source
Drawn from official USAspending contract records in our index. Always confirm requirements on the SAM.gov notice before you bid.
Intelligence only — not legal advice or a guarantee of award. Always verify requirements on the official SAM.gov notice. Past award amounts are public history, not a suggested bid or prediction. Notice ID d530a6cee29d48aa894eac0c6d236a3d.